Postoperative pain
Conditions
Interventions
Control Group:Intravenous administration of sufentanil 0.2 µg/kg 30 minutes before the end of surgery, and intravenous injection of flurbiprofen axetil 1 mg/kg 10 minutes before the end of surgery. Co
Experimental Group 1:Intravenous administration of sufentanil 0.1 µg/kg and esketamine 0.25 mg/kg 30 minutes before the end of surgery, and intravenous injection of flurbiprofen axetil 1 mg/kg 10 minu
Experimental Group 2:Intravenous administration of sufentanil 0.1 µg/kg and esketamine 0.25 mg/kg 30 minutes before the end of surgery, and intravenous injection of flurbiprofen axetil 1 mg/kg 10 minu
Sponsors
The Second Affiliated Hospital of Shantou University Medical College
Eligibility
Sex/Gender
All
Age
18 Years to 65 Years
Inclusion criteria
Inclusion criteria: 1.Diagnosed with humeral, femoral, or tibial fracture based on clinical symptoms and imaging findings, with indications for surgical treatment, scheduled for elective open reduction and internal fixation under general anesthesia with tracheal intubation or laryngeal mask, and the patient or authorized representative agrees to the use of a postoperative intravenous analgesia pump. 2.Age: 18–65 years. 3.BMI: 18.5–27.9 kg/m². 4.ASA score: I–III.
Exclusion criteria
Exclusion criteria: 1.Refusal to participate in this study. 2,Allergy to the active ingredients or excipients of esketamine or dexmedetomidine. 3.Use of sedatives or analgesics within the past month. 4.Presence of severe systemic diseases. 5.Preoperative sleep disorders. 6.Preoperative painful conditions unrelated to the fracture. 7.History of peptic ulcer and bleeding within the past month. 8.Bleeding tendency or coagulation dysfunction. 9.Increased intracranial pressure or brain injury. 10.Pregnancy or lactation. 11.Preoperative mental or psychological disorders. 12.Preoperative cognitive dysfunction.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| NRS pain score;Sleep score; | — |
Secondary
| Measure | Time frame |
|---|---|
| Quality of recovery ;Incidence of adverse reactions;Inflammatory factor levels; | — |
Countries
China
Contacts
Public ContactZhenwei Zheng
The Second Affiliated Hospital of Shantou University Medical College
Outcome results
None listed